Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
2012 (English)In: Rheumatology International, ISSN 0172-8172, E-ISSN 1437-160x, Vol. 32, no 2, 295-299 p.Article, review/survey (Refereed) Published
Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of anakinra is to competitively inhibit the local inflammatory effects of IL-1. Kineret is generally safe and well tolerated and the only major treatment-related side effects that appear are skin reactions at the injection site. Due to the relatively short half-life of anakinra, daily injection of the drug is required. This, in combination with the comparably high rates of injection-site reactions (ISRs) associated with the drug, can become a problem for the patient. The present review summarises published data concerning ISRs associated with Kineret and provides some explanations as to their cause. The objective is also to present some clinical experiences of how the ISRs can be managed.
Place, publisher, year, edition, pages
2012. Vol. 32, no 2, 295-299 p.
Anakinra, Kineret, Injection-site reactions
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-169314DOI: 10.1007/s00296-011-2096-3ISI: 000299507900002OAI: oai:DiVA.org:uu-169314DiVA: diva2:506231